Showing results (231-240 of 310) with videos related to
Sort By:
Pageof 31
The New England Journal of Medicine|July 27, 2017
Trial of Tocilizumab in Giant-Cell ArteritisJohn H Stone, Katie Tuckwell, Sophie Dimonaco, et al.Journal of Clinical Medicine|December 23, 2022
Effectiveness of Different Rituximab Doses Combined with Leflunomide in the Treatment or Retreatment of Rheumatoid Arthritis: Part 2 of a Randomized, Placebo-Controlled, Investigator-Initiated Clinical Trial (AMARA)Michaela Koehm, Ann C Foldenauer, Tanja Rossmanith, et al.Arthritis & Rheumatology (Hoboken, N.J.)|November 8, 2022
American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 5Jeffrey R Curtis, Sindhu R Johnson, Donald D Anthony, et al.Arthritis & Rheumatology (Hoboken, N.J.)|June 15, 2021
American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 2Jeffrey R Curtis, Sindhu R Johnson, Donald D Anthony, et al.Arthritis & Rheumatology (Hoboken, N.J.)|August 4, 2021
American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 3Jeffrey R Curtis, Sindhu R Johnson, Donald D Anthony, et al.Arthritis & Rheumatology (Hoboken, N.J.)|April 27, 2022
American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 4Jeffrey R Curtis, Sindhu R Johnson, Donald D Anthony, et al.Zeitschrift Fur Rheumatologie|May 5, 2025
[Annual report 2025 from the National Database of the Regional Collaborative Rheumatology Centers in Germany]Katinka Albrecht, Katja Thiele, Tobias Alexander, et al.Rheumatology (Oxford, England)|March 19, 2021
Rituximab plus leflunomide in rheumatoid arthritis: a randomized, placebo-controlled, investigator-initiated clinical trial (AMARA study)Frank Behrens, Michaela Koehm, Tanja Rossmanith, et al.Arthritis & Rheumatology (Hoboken, N.J.)|February 24, 2022
Nintedanib in Patients With Autoimmune Disease-Related Progressive Fibrosing Interstitial Lung Diseases: Subgroup Analysis of the INBUILD TrialEric L Matteson, Clive Kelly, Jörg H W Distler, et al.Arthritis & Rheumatology (Hoboken, N.J.)|June 26, 2024
Efficacy and Safety of Upadacitinib or Elsubrutinib Alone or in Combination for Patients With Systemic Lupus Erythematosus: A Phase 2 Randomized Controlled TrialJoan T Merrill, Yoshiya Tanaka, David D'Cruz, et al.Pageof 31